N-(3-(2-(4-chloro-3,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)acetamido)propyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide | 1404505-30-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 生物素及其衍生物
• 英文名称: N-(3-(2-(4-chloro-3,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)acetamido)propyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
• 英文别名: 5-[(3aS,4S,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-N-[3-[[2-(4-chloro-3,5-diphenylpyrazolo[3,4-c]pyridazin-1-yl)acetyl]amino]propyl]pentanamide
• CAS: 1404505-30-1
• 化学式: C₃₂H₃₅ClN₈O₃S
• 分子量: 647.201
• InChiKey: YOCMJNFXLJCLFM-ZRLASMASSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  45
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  168
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  sodium 2-[5-amino-3-phenyl-4-(2-phenylethynyl)-1H-pyrazol-1-yl]acetate 在 盐酸 、 N,N-二异丙基乙胺 、 N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate 、 sodium nitrite 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 17.5h， 生成 N-(3-(2-(4-chloro-3,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)acetamido)propyl)-5-((3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)pentanamide
  参考文献：
  名称：

  [EN] METHODS OF TREATING OR PREVENTING A PROTEOPATHY
  [FR] MÉTHODES POUR TRAITER OU PRÉVENIR UNE PROTÉOPATHIE

  摘要：

  本文描述了一种治疗或预防蛋白质病的方法。

  公开号：

  WO2016201266A1

文献信息

• [EN] PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME<br/>[FR] PYRAZOLOPYRIDAZINES ET MÉTHODES DE TRAITEMENT DES MALADIES DÉGÉNÉRATIVES DE LA RÉTINE ET LA PERTE D'AUDITION ASSOCIÉE AU SYNDROME DE USHER
  申请人：USHER III INITIATIVE

  公开号：WO2012148994A1

  公开（公告）日：2012-11-01

  Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

  本文描述了用于治疗视网膜退行性疾病的化合物、组合物和方法，例如视网膜色素变性、勒伯遗传性黄斑变性、综合性视网膜退行性疾病、老年性黄斑变性和厄舍综合征，以及与厄舍综合征相关的听力丧失。
• [EN] TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES<br/>[FR] TRAITEMENT DU CANCER, DE MALADIES INFLAMMATOIRES ET DE MALADIES AUTO-IMMUNES
  申请人：USHER III INITIATIVE INC

  公开号：WO2022011091A1

  公开（公告）日：2022-01-13

  The present disclosure relates to methods for the treatment or prevention of cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein. The present disclosure also relates to methods for reducing risk of developing cancer, an inflammatory disease or an autoimmune disease with compounds of the invention as disclosed herein.

  本公开涉及使用本文所披露的化合物治疗或预防癌症、炎症性疾病或自身免疫疾病的方法。本公开还涉及使用本文所披露的化合物降低患癌症、炎症性疾病或自身免疫疾病风险的方法。
• PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL-DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME
  申请人：USHER III INITIATIVE

  公开号：US20130252936A1

  公开（公告）日：2013-09-26

  Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

  本文描述了用于治疗视网膜退行性疾病（如色素性视网膜炎，Leber先天性失明，综合性视网膜退化，年龄相关性黄斑变性和Usher综合征）以及与Usher综合征相关的听力损失的化合物、组合物和方法。
• PYRAZOLOPYRIDAZINES AND METHODS FOR TREATING RETINAL DEGENERATIVE DISEASES AND HEARING LOSS ASSOCIATED WITH USHER SYNDROME
  申请人：Usher Ill Initiative, Inc.

  公开号：US20150266812A1

  公开（公告）日：2015-09-24

  Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

  本文描述了用于治疗视网膜退行性疾病（如色素性视网膜炎、勒伯先天性失明症、综合性视网膜退行性疾病、老年性黄斑部退化和Usher综合征）以及与Usher综合征相关的听力损失的化合物、组合物和方法。
• Pyrazolopyridazines and methods for treating retinal-degenerative diseases and hearing loss associated with usher syndrome
  申请人：USHER III INITIATIVE, INC.

  公开号：US10307422B2

  公开（公告）日：2019-06-04

  Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

  本文描述了用于治疗视网膜变性疾病的化合物、组合物和方法，如视网膜色素变性、勒伯氏先天性失明、综合征视网膜变性、老年性黄斑变性和乌谢尔综合征，以及与乌谢尔综合征相关的听力损失。